ARTICLE | Company News

Halozyme, AbbVie deal

June 8, 2015 7:00 AM UTC

Halozyme granted AbbVie non-exclusive, worldwide rights to develop and commercialize up to nine undisclosed AbbVie compounds in combination with Halozyme’s Enhanze drug delivery platform. Halozyme’s Enhanze platform uses recombinant human enzyme sperm adhesion molecule 1 ( SPAM1; PH20) hyaluronidase to temporarily degrade hyaluronan and improve subcutaneous delivery of injectable biologics. ...